The new generation weight-loss drug developed by the U.S. biotechnology company Metsera, Inc. (MTSR) demonstrated excellent ...

The Financial Times reports on Novo Nordisk's challenge to Pfizer, Comcast's talks to acquire ITV, Messina Group's stake sale ...

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) reported a rise in third-quarter revenue and earnings but surprised ...

Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its ...

Pfizer and Novo Nordisk’s bidding war for the weight loss drugmaker Metsera is intensifying. Five updates: 1. Pfizer matched Novo Nordisk’s $10 billion bid for the biotech firm Nov. 5, one day after ...

By TOM MURPHY, Associated Press The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. […] ...

The battle for obesity drug maker Metsera has escalated into a high-stakes bidding war between two pharmaceutical giants, ...

President Donald Trump's administration confirmed Thursday that it has reached a deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to ...

A heated bidding war has erupted between Novo Nordisk and Pfizer over U.S. biotech firm Metsera and its obesity drug assets, valued at $10 billion. Novo's higher offer has stirred tensions, with ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...